Overview
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Eligibility
Inclusion Criteria:
- Histologically documented advanced or metastatic solid tumor with KRAS G12C mutation.
Exclusion Criteria:
- Active brain metastases
- Malabsorption or other condition that interferes with enteral absorption
- Clinically significant cardiovascular dysfunction or liver disease